{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:46:53Z","timestamp":1792108013607,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018883","name":"Maurice Wilkins Centre for Molecular Biodiscovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.virol.2026.110915","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:26:17Z","timestamp":1776284777000},"page":"110915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SARS-CoV-2 variant-specific enhancement of dendritic heparan sulfate mimetic antiviral activities"],"prefix":"10.1016","volume":"620","author":[{"given":"Blake","family":"Sullivan-Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabihah","family":"Shahrudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Spijkers-Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Rendle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Steain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Zubkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Netzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.110915_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2024.115073","article-title":"Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants","volume":"332","author":"Ashley","year":"2025","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"issue":"7139","key":"10.1016\/j.virol.2026.110915_bib3","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nature05817","article-title":"Heparan sulphate proteoglycans fine-tune mammalian physiology","volume":"446","author":"Bishop","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.virol.2026.110915_bib4","series-title":"Influenza Antiviral Drug Resistance","year":"2022"},{"issue":"4","key":"10.1016\/j.virol.2026.110915_bib5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.virol.2026.110915_bib6","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.3390\/ijms22126574","article-title":"Heparan sulfate proteoglycans in viral infection and treatment: a special focus on SARS-CoV-2","volume":"22","author":"De Pasquale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.virol.2026.110915_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/pathogens14111129","article-title":"Pseudovirus-based neutralization assays as customizable and scalable tools for serological surveillance and immune profiling","volume":"14","author":"Denani","year":"2025","journal-title":"Pathogens"},{"issue":"10328","key":"10.1016\/j.virol.2026.110915_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2026.110915_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.912887","article-title":"Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants","volume":"9","author":"Gelbach","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.virol.2026.110915_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acscentsci.1c01293","article-title":"Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike\u2013ACE2 interaction","volume":"8","author":"Guimond","year":"2022","journal-title":"ACS Cent. Sci."},{"issue":"4","key":"10.1016\/j.virol.2026.110915_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cell.2022.01.001","article-title":"Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2","volume":"185","author":"Han","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.virol.2026.110915_bib12","article-title":"Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry","author":"Han","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2026.110915_bib13","article-title":"Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry","author":"Han","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2026.110915_bib14","first-page":"e01303","article-title":"Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2","author":"Higuchi","year":"2025","journal-title":"mBio"},{"issue":"7944","key":"10.1016\/j.virol.2026.110915_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2026.110915_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.virol.2026.110915_bib17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1242\/jcs.03432","article-title":"Heparan sulfate proteoglycans at a glance","volume":"120","author":"Kirkpatrick","year":"2007","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.virol.2026.110915_bib18","series-title":"Seminars in Thrombosis and Hemostasis","article-title":"Emerging roles of heparan sulfate proteoglycans in viral pathogenesis","author":"Koganti","year":"2021"},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s44298-025-00104-1","article-title":"Balancing stability and function: impact of the surface charge of SARS-CoV-2 omicron spike protein","volume":"3","author":"Lauster","year":"2025","journal-title":"Npj Viruses"},{"key":"10.1016\/j.virol.2026.110915_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120595","article-title":"Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity","volume":"267","author":"Li","year":"2022","journal-title":"Spectrochim. Acta Mol. Biomol. Spectrosc."},{"issue":"8","key":"10.1016\/j.virol.2026.110915_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00684-23","article-title":"Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides","volume":"97","author":"Llewellyn","year":"2023","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2026.110915_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02441-16","article-title":"Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors","volume":"61","author":"Lomonosova","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.virol.2026.110915_bib23","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"11","key":"10.1016\/j.virol.2026.110915_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11113099","article-title":"The role of heparin in COVID-19: an update after two years of pandemics","volume":"11","author":"Mangiafico","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.virol.2026.110915_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41579-023-01001-1","article-title":"Clinical course and management of COVID-19 in the era of widespread population immunity","volume":"22","author":"Meyerowitz","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.virol.2026.110915_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00003-19","article-title":"Antiviral candidates for treating hepatitis E virus infection","volume":"63","author":"Netzler","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.virol.2026.110915_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100681","article-title":"Charge matters: mutations in omicron variant favor binding to cells","volume":"23","author":"Nie","year":"2022","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.virol.2026.110915_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms","volume":"298","author":"Paiardi","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.virol.2026.110915_bib29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chom.2022.07.006","article-title":"Determinants of spike infectivity, processing, and neutralization in SARS-CoV-2 omicron subvariants BA. 1 and BA. 2","volume":"30","author":"Pastorio","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72262-w","article-title":"Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium","volume":"14","author":"Paull","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12974-023-02925-4","article-title":"The novel HS-mimetic, Tet-29, regulates immune cell trafficking across barriers of the CNS during inflammation","volume":"20","author":"Peck","year":"2023","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2012.06.025","article-title":"In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against enterovirus 71","volume":"169","author":"Pourianfar","year":"2012","journal-title":"Virus Res."},{"issue":"911","key":"10.1016\/j.virol.2026.110915_bib33","doi-asserted-by":"crossref","first-page":"eadr0011","DOI":"10.1126\/scisignal.adr0011","article-title":"Leukocytes have a heparan sulfate glycocalyx that regulates recruitment during psoriasis-like skin inflammation","volume":"18","author":"Priestley","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.virol.2026.110915_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.581213","article-title":"Heparan sulfate proteoglycans: key mediators of stem cell function","volume":"8","author":"Ravikumar","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.virol.2026.110915_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00203-024-04181-3","article-title":"Drug resistance and possible therapeutic options against influenza A virus infection over past years","volume":"206","author":"Raza","year":"2024","journal-title":"Arch. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/biom15010135","article-title":"Pseudotyped viruses: a useful platform for pre-clinical studies conducted in a BSL-2 laboratory setting","volume":"15","author":"Rizatdinova","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib37","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1038\/s41467-022-35312-3","article-title":"BA. 2 and BA. 5 omicron differ immunologically from both BA. 1 omicron and pre-omicron variants","volume":"13","author":"R\u00f6ssler","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.virol.2026.110915_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012211","article-title":"Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy","volume":"20","author":"Saad-Roy","year":"2024","journal-title":"PLoS Comput. Biol."},{"issue":"9","key":"10.1016\/j.virol.2026.110915_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00338-24","article-title":"SARS-CoV-2 omicron subvariants progressively adapt to human cells with altered host cell entry","volume":"9","author":"Sakurai","year":"2024","journal-title":"mSphere"},{"issue":"7","key":"10.1016\/j.virol.2026.110915_bib40","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"12","key":"10.1016\/j.virol.2026.110915_bib41","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/v14122696","article-title":"Structural characteristics of heparin binding to SARS-CoV-2 spike protein RBD of omicron sub-lineages BA. 2.12. 1, BA. 4 and BA. 5","volume":"14","author":"Shi","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2026.110915_bib42","series-title":"Created in Biorender","author":"Shields","year":"2026"},{"issue":"5","key":"10.1016\/j.virol.2026.110915_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2381","article-title":"Evolution of the SARS\u2010CoV\u20102 omicron variants BA. 1 to BA. 5: implications for immune escape and transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.virol.2026.110915_bib44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2013.00470","article-title":"Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity","volume":"4","author":"Simon Davis","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2026.110915_bib45","unstructured":"Singleton, J.B., et al., Understand This Underutilization, we Conducted a Survey to as-sess Perspectives and Barriers of Antiviral Usage for Outpatients with COVID-19 and Influenza as Perceived by Infectious Disease Specialists in North America."},{"issue":"12","key":"10.1016\/j.virol.2026.110915_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/asia.202200228","article-title":"Synthesis of novel glycolipid mimetics of heparan sulfate and their application in colorectal cancer treatment in a mouse model","volume":"17","author":"Spijkers\u2010Shaw","year":"2022","journal-title":"Chem.--Asian J."},{"issue":"13","key":"10.1016\/j.virol.2026.110915_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202316791","article-title":"Synthesis and detection of BODIPY\u2010, biotin\u2010, and 19F\u2010Labeled single\u2010entity dendritic heparan sulfate mimetics","volume":"136","author":"Spijkers\u2010Shaw","year":"2024","journal-title":"Angew. Chem."},{"issue":"4","key":"10.1016\/j.virol.2026.110915_bib48","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1021\/jacsau.3c00042","article-title":"Well-defined heparin mimetics can inhibit binding of the trimeric spike of SARS-CoV-2 in a length-dependent manner","volume":"3","author":"Sun","year":"2023","journal-title":"JACS Au"},{"issue":"5","key":"10.1016\/j.virol.2026.110915_bib49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA. 2.12. 1, BA. 4, and BA. 5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.virol.2026.110915_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01987-20","article-title":"Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives","volume":"95","author":"Tandon","year":"2021","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2026.110915_bib51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS\u2010CoV\u20102 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.virol.2026.110915_bib52","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.virol.2026.110915_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103339","article-title":"Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies","author":"van Haren","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.virol.2026.110915_bib54","article-title":"WHO COVID-19 dashboard","year":"2025","journal-title":"World Health Organization Data"},{"key":"10.1016\/j.virol.2026.110915_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060713-035314","article-title":"Demystifying heparan sulfate-protein interactions","volume":"83","author":"Xu","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.virol.2026.110915_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.117797","article-title":"Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus","volume":"260","author":"Yan","year":"2021","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-020-00222-5","article-title":"Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.virol.2026.110915_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-020-00222-5","article-title":"Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.virol.2026.110915_bib59","article-title":"Mechanism of action of small-molecule agents in ongoing clinical trials for SARS-CoV-2: a review","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.virol.2026.110915_bib60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"issue":"12","key":"10.1016\/j.virol.2026.110915_bib61","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/acschembio.8b00909","article-title":"Dendrimer heparan sulfate glycomimetics: potent heparanase inhibitors for anticancer therapy","volume":"13","author":"Zubkova","year":"2018","journal-title":"ACS Chem. Biol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:18:40Z","timestamp":1777753120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"alternative-id":["S0042682226001303"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110915","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 variant-specific enhancement of dendritic heparan sulfate mimetic antiviral activities","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110915"}}